1. Development of selective MELK kinase inhibitors for breast cancer treatment. (December 2016) Authors: Wegrzyn, P.; Kowalczyk, P.; Dobrzanska, M.; Knop, M.; Obacz, M.; Gluza, K.; Commandeur, C.; Sabiniarz, A.; Wiklik, K.; Golas, A.; Vaillancourt, F.; Larsen, N.; Wang, J.; Reynolds, D.; Ito, D.; Zou, J.; Aicher, M.; Smith, P.; Zhu, P.; Brzozka, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS. (23rd June 2022) Authors: Pakulska, U.; Angelosanto, N.; Mikula, M.; Nogai, H.; Dudziak, R.; Abboud, C.; Obacz, M.; Goller, K.; Cybulska, M.; Mazan, M.; Kozakowska, M.; Rzymski, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 350 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗